GlassScriptPhysician profile
Dylan Louis Ekstrand
NPI 1497259386
$6,482.95
in general payments reported to CMS, 2019-2025
38 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $255 · 2021: $205 · 2022: $1,039 · 2023: $1,609 · 2024: $2,012 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818 · Education: $65.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,818.29 |
| Education | $65.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $819.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $734.93 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $723.13 | 2021-2025 | |
| Lilly USA, LLC | $413.59 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $391.19 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.77 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $315.07 | 2024-2025 | Voquezna |
| Alkermes, INC. | $247.95 | 2022-2025 | Aristada, Aristada Initio, Vivitrol |
| Exact Sciences Corporation | $211.81 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.69 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $199.07 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $194.75 | 2020-2025 | |
| Abbott Laboratories | $186.51 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $130.69 | 2020 | |
| Amgen INC. | $128.23 | 2022-2025 | Evenity, Prolia, Otezla |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $127.02 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $113.65 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Medtronic, INC. | $106.62 | 2024 | Minimed 780g, Synchromedii |
| Glaxosmithkline, LLC. | $95.91 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $93.53 | 2023-2025 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $91.76 | 2022-2024 | |
| Astellas Pharma US INC | $87.97 | 2024-2025 | Veozah |
| Grifols USA, LLC | $68.17 | 2020-2023 | Prolastin-C Liquid |
| Biohaven Pharmaceutical Holding Company LTD. | $64.82 | 2022 | |
| Corcept Therapeutics | $60.64 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $48.47 | 2019-2021 | |
| Cranial Technologies, INC | $43.65 | 2019-2025 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.73 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $33.54 | 2020-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.90 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $22.47 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $21.22 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $21.02 | 2025 | Inspire |
| Cequr Corporation | $13.70 | 2024 | Cequr Simplicity |
| Antares Pharma, INC. | $13.56 | 2025 | Xyosted |
| Circassia INC. | $12.68 | 2020 | |
| Biodelivery Sciences International, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Ekstrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.